Skip to main content

Month: January 2024

Beneficient Closes Initial Series of Liquidity Transaction Financings of Limited Partner Interests Sourced Through Preferred Liquidity Provider Program (“PLP Program”)

– Closing of $2 Million Liquidity Financing Caps Nearly $10 Million Sourced from PLP Program – – Entered into additional PLP Program Agreements, Increasing the Total Amount of Committed Capital to Funds Party to the PLP Program to $1.5 Billion – – PLP Program now Offered alongside Beneficient’s New Primary Commitment Program for General Partners – DALLAS, Jan. 22, 2024 (GLOBE NEWSWIRE) — Beneficient (Nasdaq: BENF), a technology-enabled platform providing liquidity and related trust and custody services to holders of alternative assets through its proprietary AltAccess® online platform, today announced key milestones and liquidity transaction financing closings sourced through its expanding Preferred Liquidity Provider Program (“PLP Program”) for general partners. As a result of recent increased participation in the PLP Program,...

Continue reading

Solaris Commences 2024 Drilling Program at Warintza Project

VANCOUVER, British Columbia, Jan. 22, 2024 (GLOBE NEWSWIRE) — Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce a corporate update including the commencement of the 2024 drilling program at its Warintza Project (“Warintza” or “the Project”) in southeastern Ecuador. Warintza 2024 Drilling Program Underway The 2024 drilling program has commenced with the first rig turning at Warintza East and a total of six rigs planned to be in operation by the end of February. An updated mineral resource estimate is expected in late Q2/24 to take in nearly double the meterage of the prior estimate and deliver major growth at Warintza Central, East and the recent discovery of Warintza Southeast within a common pit shell. Drilling will continue through the updated mineral resource estimate with a...

Continue reading

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 22, 2024 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced the selection of a lead vaccine candidate, PMN400, against multiple synucleinopathies including Multiple System Atrophy (MSA), Parkinson’s disease and Lewy Body Dementia. “We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. “While our primary focus is on the further clinical development...

Continue reading

POET Technologies Upsizes Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 22, 2024 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Corporation“) (TSXV:PTK, NASDAQ:POET) today announces that, in response to additional interest in its non-brokered private placement previously-announced and described in the Corporation’s news releases of December 11, 2023 and January 16, 2024 (as amended, the “Offering“), the Offering will be upsized. The Offering will now consist of up to 5,100,000 units of the Corporation (the “Units“) at a price of C$1.22 (US$0.90) per Unit for aggregate gross proceeds of up to approximately C$6,222,000 million (US$4,590,000 million). The terms of the Offering are otherwise unchanged from those previously announced. Each Unit...

Continue reading

Lightbridge Announces Upcoming Industry Event and Media Interview

RESTON, Va., Jan. 22, 2024 (GLOBE NEWSWIRE) — Lightbridge Corporation (“Lightbridge”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that Lightbridge President and CEO Seth Grae will participate in upcoming industry and media events. Tuesday, January 23, 8:30 am ET – BNN Bloomberg TV’s “The Street,” hosted by Paul Bagnell Lightbridge President and CEO Seth Grae will be interviewed on BNN Bloomberg TV’s “The Street”, hosted by Paul Bagnell. Mr. Grae will discuss the commitment of the United States, Canada, and other nations at COP28 to triple global nuclear power by 2050 and the importance of Lightbridge’s nuclear fuel technology to help achieve that goal, and will also discuss Canada’s plans for increasing nuclear power generation. A livestream of BNN Bloomberg can be accessed at https://www.bnnbloomberg.ca/live. Tuesday,...

Continue reading

Xanadu Enters into New Magmatic Copper and Nickel Sulphide Project

Figure 1Sant Tolgoi Cu-Ni project is located in the Zavkhan Province approximately 1,100 km west of Ulaanbaatar, Mongolia. Project to located close to established infrastructure.Figure 2Sant Tolgoi Cu-Ni project covers two granted Exploration Licences XV-17774 (Oyut) and XV-21887 (Sant Tolgoi) a combined area of area of over 40km2.TORONTO, Jan. 22, 2024 (GLOBE NEWSWIRE) — Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) is pleased to announce it has agreed a binding term sheet with STSM LLC (STSM) granting the right to earn up to 80% interest in two exploration licences XV-17774 (Oyut) and XV-21887 (Sant Tolgoi) located in the Zavkhan Province of Western Mongolia. These two licenses make up the Sant Tolgoi Project, which is considered highly prospective for discovery of new magmatic intrusion-related...

Continue reading

Brunswick Exploration Starts Winter Drilling Campaign at Mirage

MONTREAL, Jan. 22, 2024 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to announce that it has started a Phase II drilling campaign at the Mirage project, located in the Eeyou-Istchee James Bay region of Quebec. The winter drill program is targeting extensions of known pegmatite dykes (MR-1 to MR-6) and new prospective outcrops that have yet to be drill-tested. The campaign will operate from a new BRW exploration camp located along the Trans-Taïga Road. Mr. Killian Charles, President and CEO of BRW, commented: “This will be an exciting 2024 start for BRW as we immediately commence a significant drill program at Mirage. The drilling campaign will aggressively target known dykes with wide step backs and deeper holes. It is our intention to rapidly demonstrate the potential...

Continue reading

Condor Receives Feedgas Allocation for Its LNG Project in Kazakhstan

CALGARY, Alberta, Jan. 22, 2024 (GLOBE NEWSWIRE) — Condor Energies Inc. (“Condor” or the “Company”) (TSX:CDR), a Canadian based energy transition company is pleased to announce that it has received a natural gas allocation (the “Gas Allocation”) from the Government of the Republic of Kazakhstan (Kazakhstan”). The Gas Allocation will be used as feed gas for the Company’s first modular liquefied natural gas (“LNG”) production facility. The feed gas will be liquefied to produce up to 350 Tonnes per day (210,000 gallons per day) of LNG, which can fuel approximately 125 rail locomotives or 215 large mine haul trucks (150 Tonne haul capacity). The CO2 emission reductions associated with using this LNG volume to displace diesel fuel equates to removing over 31,000 cars from service annually. The Company has also acquired 12 hectares of...

Continue reading

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

PDUFA Goal date is November 16, 2024 Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2024LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for obecabtagene autoleucel (obe-cel) for patients with relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of November 16, 2024, a standard review timeline consistent with recently approved CAR T therapies. The FDA is not currently planning to hold an advisory...

Continue reading

Talisker Intersects 28.58 g/t Au over 6.35 Metres from the Bralorne Gold Project Resource Conversion Program

Figure 1Plan view section of holes SB-2023-012 and 2023-023 drilling within the proposed Mustang Mine footprint.Figure 2Hole SB-2023-012 intersection on the BK Vein.Figure 3Hole SB-2023-023 intersections on the BK and Alhambra Veins.TORONTO, Jan. 22, 2024 (GLOBE NEWSWIRE) — Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX:TSK | OTCQX:TSKFF) is pleased to announce additional high-grade drill results highlighted by 80.68 g/t Au over 2.20 metres within a broader interval of 28.58 g/t over 6.35 metres at its 100% owned flagship Bralorne Gold Project. Key Points:Talisker initiated resource conversion drilling on October 17, 2023 with 15,000 metres of planned drilling. Hole SB-2023-023 intersected 80.68 g/t Au over 2.20 metres within a broader interval of 28.58 g/t Au over 6.35 metres on the BK...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.